| BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome (NCT04563195) | Matthew C. Baker | 2022-02-01 |
| The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome (NCT04981145) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-01-14 |
| Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome (NCT05087589) | Peking University People's Hospital | 2021-11-20 |
| The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (NCT04975087) | Gazi University | 2021-10-15 |
| Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients (NCT04605978) | Institut de Recherches Internationales Servier | 2021-08-03 |
| Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire (NCT04858464) | Gazi University | 2021-05-02 |
| BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome (NCT04684654) | Bristol-Myers Squibb | 2021-02-16 |
| Clinical Study of Jianfei Kangfu Cao in the Treatment of pSS-ILD (NCT04544722) | Shanghai University of Traditional Chinese Medicine | 2020-10-01 |
| A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome (NCT04078386) | RemeGen Co., Ltd. | 2019-11-21 |
| Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease (NCT04212572) | University Hospital, Brest | 2019-11-20 |
| A Study of INCB050465 in Primary Sjögren's Syndrome (NCT03627065) | Incyte Corporation | 2019-02-28 |
| Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity (NCT03003572) | Centre Hospitalier Universitaire de Saint Etienne | 2018-03-27 |
| The ASSESS National Multi-center Prospective Cohort (NCT03040583) | Assistance Publique - Hôpitaux de Paris | 2016-09-01 |
| Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome (NCT02775916) | Novartis Pharmaceuticals | 2016-06-01 |
| Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome (NCT02495129) | Novartis Pharmaceuticals | 2015-12-01 |
| UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome (NCT02610543) | UCB Celltech | 2015-10-01 |
| A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome (NCT02464319) | Peking University People's Hospital | 2015-06-01 |
| Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome (NCT02291029) | Novartis Pharmaceuticals | 2014-10-22 |
| PD of VAY736 in Patients With Primary Sjögren's Syndrome (NCT02149420) | Novartis Pharmaceuticals | 2014-05-23 |
| Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study (NCT02027298) | The Cleveland Clinic | 2013-11-01 |
| Primary Sjögren Syndrome (NCT01989819) | University Hospital, Limoges | 2012-09-01 |
| Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome (NCT01552681) | National Institute of Allergy and Infectious Diseases (NIAID) | 2012-07-01 |
| Exercise in Sjogren, Myositis and Takayasu's Arteritis (NCT01501019) | University of Sao Paulo | 2011-10-01 |
| Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome (NCT00632866) | Assistance Publique - Hôpitaux de Paris | 2008-03-01 |
| Confocal Microscopy and Lacrimal Gland in Sjogren's Syndrome (NCT00920179) | Keio University | 2007-10-01 |
| Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome (NCT00426543) | University of Copenhagen | 2007-01-01 |
| Mycophenolate Sodium Treatment in Patients With Primary Sjogren's Syndrome (NCT00542763) | University Hospital Muenster | 2005-04-01 |